Sentences with phrase «from lymphoma patients»

Our current methods of generating the CD40 - B vaccine from lymphoma patients are laborintensive and require specialized laboratory equipment that is not available in most facilities.

Not exact matches

Over the next few hours, he'll use the da Vinci to cut out a lymph node from the patient (who suffers from lymphoma) for lab testing.

Novartis, for example, spent $ 43 million on a manufacturing facility in Morris Plains, New Jersey, and last week it released results from a lymphoma trial in which cells were frozen and flown to and from patients in 10 countries.

However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.

Even lymphoma patients who were «bacteria - free» benefited from a three - week course of doxycycline therapy, and showed complete remission of the disease.

Professor Gandhi said results from a landmark study regarding the tool would help clinicians identify the best course of action for patients with Diffuse Large B - Cell Lymphoma (DLBCL).

From patient medical records, they obtained detailed information on treatments, which they used to estimate radiation doses to the stomach and to calculate the doses and types of chemotherapy that were used to treat the survivors» Hodgkin lymphoma.

The lab of Elisa Oricchio at EPFL, with colleagues from the US and Canada, analyzed the genomes of over 200 follicular lymphoma patients.

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL)-- a rare type of non-Hodgkin lymphoma that affects the skin.

Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft - versus - host disease (GvHD) after therapeutic bone marrow transplants.

Researchers tracked heart failure cases in 1,550 people without cancer and in 900 breast cancer and lymphoma patients in Olmsted County, Minnesota, from 1985 to 2010.

A unique approach to targeting the abnormal T - cells that cause T - cell lymphomas could offer hope to patients with the aggressive and difficult - to - treat family of cancers, finds a study involving researchers from Cardiff University.

One - year transplant - related death was 5.2 percent and resulted from recurrence / persistence of the lymphoma, fungal infection, and cardiac arrest, which was comparable to the non-HIV patients.

While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy.

Data from 29 patients from the single - arm trial in relapsed follicular lymphoma patients showed a 66 % (19 patients) overall response rate — 15 patients were complete responses and 4 patients were partial responses.

Current treatment options for patients, aside from watchful waiting, include chemotherapy and rituximab, which was approved for first - line follicular lymphoma in 2006.

According to The National Cancer Institute, 8,260 people in the United States were diagnosed with Hodgkin lymphoma last year and approximately 1,070 patients with non-Hodgkin lymphoma died from the disease in 2017.

The percentage of Hodgkin lymphoma and Wilms tumor patients treated with radiation fell from 96 to 77 percent and 77 to 49 percent respectively.

The study will enroll patients with acute myeloid leukemia (AML) and is supported by a $ 3.5 million investment from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program ®.

Because many diseases, such as leukemia, lymphoma, myeloma and myelodysplasia, are more common in older patients, mini-HCTs allow these patients to potentially benefit from transplant.

The outcome of peripheral T - cell lymphoma patients failing first line therapy: a report from the prospective, international T - Cell project.

Positron emission tomography (PET) imaging of metabolic tumor burden at diagnosis and after induction therapy can help identify patients most at risk of follicular lymphoma (FL) recurrence, but more work is needed to differentiate high - risk and moderate - risk patients, suggested findings from a pooled analysis of data from three prospective clinical trials, published in Blood.

Current practice is therefore based on findings from early - phase and retrospective primary CNS lymphoma studies, and extrapolations of survival data among patients with systemic B - cell lymphoma, Dr. Doorduijn said.

«Both total metabolic tumor volume (TMTV), computed on baseline PET, and end - of - induction PET (EOI PET) are imaging biomarkers showing promise for early risk stratification in patients with high tumor - burden follicular lymphoma,» reported lead author Anne Ségolène Cottereau, MD, from Cochin Hospital, René Descartes University, Paris, France, and colleagues.

Using data from the Stanford Hodgkin's Disease Database from 1966 to 1999, Horst et al retrospectively reviewed 147 patients with a history of Hodgkin lymphoma and chest RT who subsequently developed breast cancer.

The new results — from trials for patients with advanced lymphoma, multiple myeloma, and pancreatic cancer — expand on Penn's work with chimeric antigen receptor (CAR) therapies, building on findings in patients with chronic lymphocytic leukemia and acute lymphoblastic leukemia dating back to the start of the first clinical trial in 2010.

We have confirmed lymphoma and we know the average life expectancy for a patient with untreated lymphoma is about 2 months from the time of diagnosis.

Most internal lymphoma canine patients that do not receive treatment will die from the disease in as little as 3 or 4 weeks.

The lymphoma clinical trials investigate harnessing the immune system of the patient to help clear the tumor cells from the body.

He also wrote a book, published in 2006, about his battle with mantle cell lymphoma, Patient from Hell.